[HTML][HTML] Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
L Zhong, Y Li, L **ong, W Wang, M Wu… - Signal transduction and …, 2021 - nature.com
Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …
Advances in acute myeloid leukemia
LF Newell, RJ Cook - Bmj, 2021 - bmj.com
Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with
historically high mortality rates. The standard of care treatment remained unchanged for …
historically high mortality rates. The standard of care treatment remained unchanged for …
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs
ST Diepstraten, MA Anderson, PE Czabotar… - Nature Reviews …, 2022 - nature.com
Apoptosis is a form of programmed cell death that is regulated by the balance between
prosurvival and proapoptotic BCL-2 protein family members. Evasion of apoptosis is a …
prosurvival and proapoptotic BCL-2 protein family members. Evasion of apoptosis is a …
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
AH Wei, P Montesinos, V Ivanov… - Blood, The Journal …, 2020 - ashpublications.org
Effective treatment options are limited for patients with acute myeloid leukemia (AML) who
cannot tolerate intensive chemotherapy. Adults age≥ 18 years with newly diagnosed AML …
cannot tolerate intensive chemotherapy. Adults age≥ 18 years with newly diagnosed AML …
Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia
Background Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically
overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We …
overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We …
Venetoclax and obinutuzumab in patients with CLL and coexisting conditions
Background The BCL2 inhibitor venetoclax has shown activity in patients with chronic
lymphocytic leukemia (CLL), but its efficacy in combination with other agents in patients with …
lymphocytic leukemia (CLL), but its efficacy in combination with other agents in patients with …
Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study
AH Wei, SA Strickland Jr, JZ Hou, W Fiedler… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE Effective treatment options are limited for patients with acute myeloid leukemia
(AML) who cannot tolerate intensive chemotherapy. An international phase Ib/II study …
(AML) who cannot tolerate intensive chemotherapy. An international phase Ib/II study …
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
Members of the B cell lymphoma 2 (BCL-2) gene family have a central role in regulating
programmed cell death by controlling pro-apoptotic and anti-apoptotic intracellular signals …
programmed cell death by controlling pro-apoptotic and anti-apoptotic intracellular signals …
Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting
U Jäger, W Barcellini, CM Broome, MA Gertz, A Hill… - Blood reviews, 2020 - Elsevier
Autoimmune hemolytic anemias (AIHAs) are rare and heterogeneous disorders
characterized by the destruction of red blood cells through warm or cold antibodies. There is …
characterized by the destruction of red blood cells through warm or cold antibodies. There is …